BIOCON GENERICS INC

Form 483 issued September 8, 2020 · Cranbury, New Jersey

Inspection
Aug 25 – Sep 8, 2020
Observations
3
Pages
5
FEI number
3014086465

In short: On September 8, 2020, FDA issued a Form 483 with 3 observations to BIOCON GENERICS INC in Cranbury, New Jersey (FEI 3014086465) after an inspection that ran Aug 25 – Sep 8, 2020. The investigators were Annet R. Rajan and Yvins Dezan. Most observations concern quality system and laboratory controls.

At a glance

Quality system and laboratory controls account for 2 of 3 observations.

Quality system1
Laboratory controls1
Facilities & equipment1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The responsibilities and procedures applicable to the quality control unit are not in…

  2. 02

    Laboratory records are deficient in that they do not include a complete record of all…

  3. 03

    Appropriate controls are not exercised over computers or related systems to assure that changes in master…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at BIOCON GENERICS INC?

FDA listed 3 observations on this Form 483, mostly about quality system, laboratory controls and facilities & equipment. The opening words of each observation are shown on this page.

Who inspected BIOCON GENERICS INC?

Annet R. Rajan and Yvins Dezan are named on this Form 483, for the inspection of Aug 25 – Sep 8, 2020. Each investigator has a profile showing what they cite most.

When was BIOCON GENERICS INC inspected by FDA?

The inspection ran Aug 25 – Sep 8, 2020, and the Form 483 is dated September 8, 2020.

How do I get the full Form 483 for BIOCON GENERICS INC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free